Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

NCT02639351 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL: Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R
BIOLOGICAL: Investigational MenC-CRM adjuavnted with 25 ug of LHD153R
BIOLOGICAL: Investigational MenC-CRM adjuavnted with 50 ug of LHD153R
BIOLOGICAL: Investigational MenC-CRM adjuavnted with 100 ug of LHD153R
BIOLOGICAL: Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)

Sponsor

GlaxoSmithKline